The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.

Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, M. R., Walker, K. J., Turkes, A., Blamey, R. W., Nicholson, R. I.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001373/
https://www.ncbi.nlm.nih.gov/pubmed/2941044
Descripción
Sumario:Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.

Ejemplares similares